Verona Pharma on the Brink of a Breakthrough: Ohtuvayre is Aiming for Blockbuster Status. Wolfe Research Sees Room for up to $170 (+80%).

Verona Pharma (VRNA) is a biopharmaceutical company specializing in the development and marketing of innovative therapies for chronic respiratory diseases. The focus is particularly on the treatment of chronic obstructive pulmonary disease (COPD), one of the leading causes of morbidity and mortality worldwide. The flagship product Ohtuvayre (Ensifentrine) is approved in the USA as the first representative of a new class of drugs – a selective dual PDE3/4 inhibitor – for maintenance therapy in COPD. Verona adopts a research-driven approach and...